ClinicalTrials.gg
Not yet recruitingNCT07445191Updated Mar 3, 2026

Efficacy of Triamcinolone-Lidocaine Mix in Trigger Points Injection of Masseter Muscle: Double-blinded, Randomized Controlled Trial

A Phase 2/3 interventional study of Saline and Triamcinolone with lidocaine in TMJ Pain, sponsored by Cairo University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Cairo University · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing triamcinolone in Pain — 6 open to participants now, 6 under way, 3 of them phase 3. Triamcinolone · Pain.

Planned enrollment
17th of 21
30 · median 70
Started
2026
with 1 other
Phase 2/3
Only one
of the 21
Registered
19th of 21
by date
Lead sponsor
1 of 21
Cairo University

Among the 21 studies testing triamcinolone in Pain, this one is the 17th largest by planned enrollment, is one of 2 that started in 2026, is the only one in phase 2/3, and was the 19th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

6 of the 21 studies testing triamcinolone in Pain are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About triamcinolone

Triamcinolone: first FDA approval 1957 (ARISTOCORT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing triamcinolone in Pain, or all of them as a file.
02

Study summary

This study aims to clinically evaluate the efficacy of trigger points using active drug mix (Triamcinolone with lidocaine) on relief of myofascial pain of jaw muscle.

03

Conditions studied

  • TMJ Pain

Browse trials for

Keywords

  • masseter muscle
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age more than or equal 18 years
  2. Both sexes
  3. Patients' willingness to follow instructions

Exclusion criteria

Exclusion criteria

  1. Patients who will be using any medications to reduce the pain and/or have any effect on the skeletal muscle
  2. Clinical conditions such as pregnancy
  3. Medical problems that may interfere with the procedures such as bleeding disorders
  4. Cognitive impairment or exhibited inadequate cooperation
  5. Patients will be receiving physical therapy or wearing occlusal splint in the same period of the research
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Saline

    Drug: Saline

  • Experimental
    Triamcinolone with lidocaine

    Drug: Triamcinolone with lidocaine

  • Experimental
    Lidocaine

    Drug: Lidocaine

Interventions

06

What researchers measure

Primary outcomes

  1. current pain intensity

    • Patients' subjective pain experience. Each patient will be asked to rate his or her current and worst pain intensity on visual analogue scale (VAS) of 0-10 with zero being no pain and ten corresponds to the worst pain that the patient ever had

    Time frame: 1 week , 1 month , 3 months after treatment

Secondary outcomes

  1. maximum mouth opening

    * Maximum mouth opening (MMO). Assessment of MMO will be performed by measuring the distance in mm between the incisal edges of the upper and lower central incisors using a ruler. * The postoperative demand for analgesics will be evaluated by recording the number of the analgesic's intake. * Patient satisfaction. * Pressure pain threshold (PPT). Data will be collected preoperatively, pain will be measured immediately after the treatment, as well as one week, one month, and 3 months after the end of the treatment sessions

    Time frame: 1 week , 1 month , 3 months after treatment

  2. post operative demands for analgesics

    measuring unit number

    Time frame: 1 week , 1 month , 3 months after treatment

  3. patient satisfaction

    measured by likert scale

    Time frame: 1 week , 1 month , 3 months after treatment

  4. pressure pain threshold (PPT)

    measuresd by algometer

    Time frame: 1 week , 1 month , 3 months after treatment

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Jun 2026, 3 months later.

Of 35 non-industry phase 2/3 interventional studies under Pain, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 3 months is below that.

Counting every sponsor, half of 41 studies reached it within 20 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2026
First posted
Mar 3, 2026
StartEst.
Mar 1, 2026
Primary completionEst.
Jun 1, 2026
CompletionEst.
Jul 1, 2026
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07445191
Lead sponsor
Cairo University
Responsible party
Ammar Ali Mudhsh Al hawbani (AAMAHawbani, Cairo University) — Principal investigator
First posted
Mar 3, 2026
Start date
Mar 1, 2026 (estimated)
Primary completion
Jun 1, 2026 (estimated)
Completion
Jul 1, 2026 (estimated)
Last update
Mar 3, 2026

Study contacts

Ammar Ali Mudhsh Al-Hawbani Ammar Ali Mudhsh Al-Hawbani, bachelor's degree
Contact
prof.hamidarefaee@gmail.com
0103052078
Hamida Refai Hasanien Hasanien professor, phd
Contact
01013052078
Hamida Refai Hasanien Hasanien Hamida Refai Hasanien, phd
study director · cair university

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Triamcinolone · Lidocaine

Start the discussion